INTRODUCTION
Prostate cancer (PCa) remains the second most frequent type of cancer diagnosed worldwide, and the third leading cause of cancer-related death in men in industrialized countries (1) . Prostate cancer is an adenocarcinoma originating from cells of epithelial type, but displays morphologically and genetically very heterogeneous properties (2) . Androgens are among the main factors controlling the initiation, maintenance and progression of prostate cancer (3) .
During carcinogenesis, epithelial cells transform into a malignant phenotype, where the androgen receptor (AR) selectively activates genes positively controlling cell viability to unrestraint epithelial cell proliferation (3) . For this reason, Androgen Deprivation Therapy (ADTh), also called "medical castration" or "hormone therapy" has become a first-line treatment strategy for advanced PCa (4) . ADTh is achieved using gonadotropin releasing hormone (Gn-RH) analogs such as leuprolide, buserelin or goserelin (4) , which inhibit testosterone synthesis (2) . This medical castration is often combined to anti-androgens such as flutamide, nitulamide or bicalutamide (2) . These AR antagonists provide an additional blockade of androgen signalling by preventing AR activation by the locally synthesized androgens. Symptomatic (improvement of quality of life) and/or objective (serum PSA level normalization and measurable tumor response) outcomes to androgen deprivation therapy are observed in approximately 80% of patients (5) . However, the duration of these improvements is highly variable, and PCa relapses in the majority of patients evolving to the androgen-independent phenotype within 12 to 18 months of therapy (5) . The cancer is then commonly referred to as "castrate resistant prostate cancer" (CRPC), "androgen independent", or "hormone refractory" (6) . CRPC can transiently be treated with alternative ADTh, but the ultimate options for androgen-independent metastatic prostate cancer consists in chemotherapy (5, 7).
The androgen axis continues to play a major role for the progression of CRPCs (8) , and a deep understanding of factors affecting androgen inactivation in tumor cells is required. In the prostate, the active hormone dihydrotestosterone (DHT) is extensively metabolized in the prostate to inactive and easily excretable androstane-3α-diol-glucuronide (3α-diol-17G) and androsterone-glucuronide (ADT-3G) derivatives (9, 10) . These polar metabolites are formed through a conjugation reaction called glucuronidation, and correspond to the major androgen 4 metabolic end-products found in circulation in men (11, 12) . In humans, glucuronidation is catalyzed by the 19 functional UDP-glucuronosyltransferase (UGT) enzymes (13) . However, in prostate, androgen glucuronidation only involves 2 enzymes: UGT2B15 and UGT2B17 (14) .
Experimental inhibition of these enzymes significantly improves the pro-proliferative properties of DHT in PCa cells (14) , suggesting that they are major determinants for the androgen response. Accordingly, positive associations were reported between PCa risk and a low-activity UGT2B15 allele or a complete UGT2B17 gene deletion (15) (16) (17) (18) (19) . On the other hand, various studies illustrated the negative control that androgens exert on UGT2B15 and UGT2B17 expression in PCa cells (14, 20, 21) . These last observations establish the AR regulatory pathway as a major mechanism for controlling androgen glucuronidation. We therefore sought to test the possibility that ADTh drugs affect UGT2B15 and/or UGT2B17 expression or activity in PCa tumor samples and cell models exposed to anti-androgens. 
MATERIALS AND METHODS

Materials
UDP-glucuronic acid and all aglycons were obtained from Sigma (St. Louis, MO) or ICNPharmaceuticals Inc. (Québec, Canada). R1881, 3α-Diol, DHT, ADT, and DHT-glucuronide (DHT-G) were purchased from Steraloids (Newport, RI). ADT-3-glucuronide and 3α-Diol-17-glucuronide were provided by the Medicinal Chemistry Division of the "Centre de recherche du CHU-Québec" (21) . Cell culture materials, blasticidin and lipofectin were purchased from Invitrogen (Burlington, ON, Canada). Penicillin, streptomycin and IMDM were provided by Wisent (Rocklin, CA), while puromycin, doxycyclin, bicalutamide, nilutamide, flutamide and RPMI were purchased from Sigma. Sybr Green PCR Master mix was purchased from Applied Biosystem (Life Technologies, Carlsbad, CA). Protein assay reagents were obtained from BioRad Laboratories Inc. (Marnes-la-Coquette, France). The anti-calnexin antibody was purchased from Stressgen (Victoria, Canada), the anti-vimentin antibody was from GenScript (Piscataway, NJ), and the anti-UGT2B15 and anti-UGT2B17 antibodies were described previously (24, 31) .
The secondary antibody against rabbit IgG was purchased from Amersham (Pittsburg, PA). The chemiluminescence kit (ECL) was from Renaissance (Québec, Canada). SiRNA probe for UGT2B15/UGT2B17 (Individual siGENOME duplex D-020195-01) and Non-Target #1 were obtained from Dharmacon (Chicago, IL) as already described (14) .
Tissue banks
Tissues used for the microarray construction were from the Vancouver Prostate Centre Tissue Bank (http://www.prostatecentre.com/our-research/core-facilities/biorepository), as described (22, 23) . Prostate samples were from 31 benign prostatic hyperplasia (BPH) donors while PCa samples were from 88 advanced patients: 16 from untreated donors, 16 from participants with CRPC, and finally 56 from patients having received ADTh for 1 to 5 months (n=19), 6 to 8 months (n=24) or 9 to 12 months (n=13) (supplementary material SM1). Tissues samples were extracted from the whole tissue after radical prostatectomy, except CRPC samples which were obtained by transurethral resection of the prostate (22, 23) . The therapy 6 consisted in Gn-RH analogs (buserelin, leuprolide or goserelin) and anti-androgens (flutamide, cyprosterone acetate or bicalutamide) used alone or in combination. This protocol was approved by the institutional review boards at the University of British Columbia (Vancouver, BC, Canada), and the "Centre hospitalier universitaire de Québec" (Québec, QC, Canada).
Written informed consent was obtained from all participants.
Tissue microarrays
Microarrays and immunohistochemical (IHC) stains were obtained as previously described (22, 23) , with formalin-fixed and paraffin-embedded 4µm sections of the microarray, using the previously described (24, 31, 40) 
Cell culture
Cell lines were obtained from the American Type Culture Collection (Rockville, MD, Cell authentication through STR profiling), used within the 6 months following reception. LNCaP cells were grown and treated in the 10% FBS-supplemented RPMI 1640 medium. LAPC-4 cells were cultured in IMDM completed with 7.5% FBS and 10nM R1881. Inducible AR-shRNA-expressingLNCaP cells were cultured in RPMI 1640 supplemented with 10% FBS, puromycin (2.5µg/ml) and blasticidin (1µg/ml), as reported (28) . AR deficiency was obtained through a 48H pretreatment with doxycycline (DOX, 1µg/ml), and the antibiotic was maintained for the complete treatment duration as recommended (28 concentrations.Knock-down of UGT2B15 and UGT2B17 expression was obtained using a UGT2B15/UGT2B17 siRNA probe as already reported (14) . Following transfection, cells were allowed 18H for recovery, transferred in 96-wells plates and exposed to vehicle (DMSO, 0.1%, v/v) or bicalutamide (10µM) for 72H. Cell proliferation was then ensured using the CellTiter 96
Aqueous One Solution Cell Proliferation Assay kit (Promega, Madison, WI) and optical density determination (490nm) with a microplate reader Tecan Infinitte M1000 (Männedorf, Switzerland)
as recommended by the supplier (Promega).
Genotyping of the UGT2B17 gene copy number variation (CNV)
Genomic DNA was isolated from LNCaP and LAPC-4 cells using the ChargeSwitch gDNA Mini Tissue Kit (Life Technologies) and was then used as a template for UGT2B17 deletion genotyping as previously described (23, 26) .
RNA Isolation and quantitative RT-PCR
Total RNA was isolated according to the Tri-Reagent acid: phenol protocol as specified by the supplier (Molecular Research Center Inc., Cincinnati, OH). The reverse transcription (RT) and quantitative PCR reactions were performed as previously described (23) .
Western-blot analyses and in vitro glucuronidation
Western-blot analyses and in vitro glucuronidation assays were performed as previously reported (14, 21, 24) .
Statistical analyses
All data are presented as mean±standard deviation (SD), except for the IHC intensity evaluation where results are presented as mean±standard error to the mean (SEM).
Comparisons between experimental groups were performed by a two-tailord Student's t-test or a Mann-Whitney U test for in vivo assessment of UGT levels using the JMP V7.01 software (SAS Institute, Cary, NC). 
RESULTS
Androgen ablation therapy modulates UGT2B15 and UGT2B17 protein levels in prostate tumors
According to our previous observation (23), untreated PCa samples presented similar UGT2B15 and UGT2B17 protein levels as in BPH samples (Fig.1, SM2-8 ). However, when compared to BPH and untreated samples, both UGT proteins were significantly more abundant in tissues from ADTh-treated patients for 1 to 5 months (Fig.1, SM2-5 ). The highest UGT2B15 expression was observed after 6-8 months of treatment, and remained significantly higher than in untreated samples up to 12 months therapy, even if a tendency to lower again was observed in these last samples (Fig.1A) . By contrast, UGT2B17 protein levels were reduced to basal levels (untreated) as soon as after a 6-8 months period of treatment and remained stable for longer exposures (Fig.1B) . In patients with CRPCs, both UGT2B15 and UGT2B17 protein levels were not significantly different from in untreated samples. IHC results obtained with the positive control, vimentin (25) indicated that the quantification of UGT2B protein levels was not biased by the tissue preparation (SM2-8).
Androgen receptor antagonism up-regulates UGT2B15 and UGT2B17 expression and activity in prostate cancer cell models
Ex vivo experiments were performed using PCa cell models and AR antagonists to further investigate the effects and consequences of AR blockade on androgen glucuronidation (Figs.2-4) .
First, UGT2B15 and UGT2B17 mRNA and protein levels were quantified in LNCaP cells exposed to increasing doses of bicalutamide (0.1 to 20µM) for 48H. The two UGTs were dosedependently increased at both mRNA and protein levels (Fig.2) . While the amount of UGT2B15 transcripts was statistically increased in the presence of as low as 1µM ( Fig.2A) , UGT2B17 mRNA accumulation reached the statistical significance only in the presence of 5µM bicalutamide (Fig.2B) . In time-course experiments, UGT2B15 and UGT2B17 transcripts were significantly increased as soon as after 12H of treatment, and the maximal induction was reached after a 48H exposure (Fig.2C-D was observed for both UGT proteins in western-blot analyses (Fig.2) . In vitro glucuronidation assays confirmed that the bicalutamide-dependent increase in UGT expression results in improved androgen conjugation (Fig.3) . Indeed, LNCaP cells exposed to bicalutamide exhibited a dose-and time-dependent improved ability to conjugate DHT (A&D), ADT (B&E) and 3α-Diol (C&F).
To ascertain that results from bicalutamide-treated LNCaP cells were not cell type-or antagonist-specific, additional experiments were performed using the LAPC-4 cell model, and the other AR antagonists, nilutamide and flutamide (Fig.4) . In LAPC-4, bicalutamide dose-and time-dependently induced UGT2B15 expression (Fig.4A&B) . UGT2B17 transcripts were not detected in these cells. Actually, genotyping analyses revealed that the UGT2B17 gene is absent in LAPC-4 (data not shown), indicating their del/del phenotype for the previously reported UGT2B17 CNV genotype (26) . In both LNCaP and LAPC-4 cells, bicalutamide and flutamide were efficient in increasing UGT2B15 mRNA levels (Fig.4C&D) . A similar response was also observed for UGT2B17 transcripts in LNCaP cells (Fig.4C) . Interestingly, nilutamide exhibited a cell-specific response with a significant induction of UGT2B15 mRNA in LAPC-4 but not in LNCaP cells (Fig.4C&D) . Furthermore, not only did nilutamide not improve UGT2B17 expression, but it caused a non significant reduction of these transcripts in LNCaP cells (Fig.4C ). This last observation is consistent with the previously reported agonistic effects of nilutamide in front of the mutated AR that is expressed in LNCaP cells (27) .
The androgen receptor mediates the bicalutamide-dependent up-regulation of UGT2B15 and UGT2B17 expression in LNCaP cells
AR contribution to the bicalutamide-dependent induction of UGT2B15 and UGT2B17 expression was ensured by using LNCaP cells expressing a DOX-inducible anti-AR shRNA (Fig.5) (28) . We first confirmed that doxycycline treatment resulted in impaired AR expression and activity (SM9) (28) . Subsequently, native (DOX-) and doxycycline-activated cells (DOX+) were cultured in the presence of vehicle, bicalutamide (10µM), or the synthetic (R1881, 1nM) or natural (DHT, 10nM) AR activators (Fig.5) .
In native (DOX-) cells, DHT, R1881 and bicalutamide caused the expected down- (Fig.5A) and UGT2B17 (Fig.5B) mRNA expression.
In AR-deficient (DOX+) cells, doxycycline alone also significantly increased the UGT2B15 (Fig.5A) and UGT2B17 (Fig.5B) transcript levels, thus revealing that inhibition of AR expression has similar consequences as the use of AR antagonists for these UGT gene expression. The addition of R1881 in culture media had no further impact on mRNA levels of the 2 UGTs (Fig.5) . Similarly, the negative effect of DHT on UGT2B15 expression was completely lost, since its mRNA levels in vehicle-and DHT-treated DOX+ cells were not significantly different (Fig.5A) . By contrast, UGT2B17 mRNA levels were found significantly more abundant in DHT-treated than in vehicle DOX+ cells (Fig.5B) . Also surprising was the observation that bicalutamide reduces UGT2B15 and UGT2B17 mRNA levels in cells cultured with doxycycline (Fig.5 ). This last observation suggests that bicalutamide exerts opposite effects on UGT genes expression in the presence of high (DOX-) or low (DOX+) AR levels. However, when mRNA levels were compared to those quantified in bicalutamide-treated native cells, only the strong reduction in UGT2B17 transcripts remained statistically significant (Fig.5B) , indicating that the loss of AR mainly altered the response of this enzyme to bicalutamide.
Nonetheless, the fact that AR knock-down abolishes or reverses the effects of bicalutamide confirms the role played by this receptor in the anti-androgen-induced upregulation of UGT2B15 and UGT2B17 expression.
Knock-down of UGT2B15 and UGT2B17 reduces the anti-proliferative properties of bicalutamide
We next evaluated whether induction of UGT2B15 and UGT2B17 expression participates to the anti-proliferative properties of bicalutamide (29) . For this purpose, LNCaP cells were transfected with a non-target (siRNA control) or the anti-UGT2B15/UGT2B17 siRNA probe (14) (Fig.6A) , and then exposed to vehicle (DMSO) or bicalutamide (10µM) for up to 4 days (Fig.6B) . As expected (29) , bicalutamide caused a significant 24.5% reduction of control cells proliferation after 3 days of exposure. This reduction was further enhanced to 32.5% inhibition after 4 days (Fig.6B) . Interestingly, UGT2B-deficient cells were less sensitive to the (Fig.6B) . Thus, siRNA-mediated knock-down of UGT2B15 and UGT2B17 expression provoked 40% and 32% reductions of the anti-proliferative effects of bicalutamide in LNCaP cells exposed to the drug for 3 and 4 days, respectively. 
DISCUSSION
This study evidences a novel and incidental effect by which androgen ablation drugs abolish the ability of carcinogenic androgens to inhibit their own inactivation in prostate cancer cells. This first comprehensive analysis of AR blockade consequences for androgen glucuronidation identifies the 2 androgen-conjugating UGT2B15 and UGT2B17 enzymes as ADTh positive targets, and establishes the major contribution of these effects to the antiproliferative properties of ADTh drugs.
An interesting observation of the present study is the differential manner in which the 2 UGT genes respond to AR blockade in and ex vivo. These differences are thought to reflect variations in the AR-dependent modulation of the 2 UGT genes. Indeed, the fact that AR agonists/antagonists fail to modulate UGT2B15 expression in receptor-deficient cells, while having inverse effects on UGT2B17 mRNA levels, suggest that alternative regulatory processes drastically modify the AR-dependent modulation of UGT2B17 expression when the androgen receptor is reduced. While thorough investigations are required to fully grasp the mechanisms governing the molecular switch in the UGT2B17 response, it can be envisioned that such UGTspecific processes may be derived from nucleic acid differences in the transcriptional regulatory regions of the UGT2B15 and UGT2B17 genes. Even if the 2 genes share considerable sequence homology (9) , previous studies already illustrated that minor differences in their proximal promoters are responsible for their differential response to various regulatory pathways (30, 31) . Such changes actually exist within the AR response elements identified in UGT2B15 and UGT2B17 promoters sequences (20) , and thus may play a role in their isoform-specific response under low AR levels. Other regulatory pathways may also be involved. For example, the epidermal growth factor (EGF) signalling, which down-regulates UGT2B17 expression without affecting UGT2B15 in LNCaP cells (31) , has been identified as a transduction pathway involved in prostate tumor growth (32, 33) . (8, 34) . Since AR acts as a negative UGT2B15 and UGT2B17 genes regulator (14, 20, 21) , the loss of UGT induction detected in vivo may actually reflect an AR reactivation in resistant tumors. On the other hand, as observed with UGT knockdown experiments, the induction of androgen glucuronidation may contribute to the antiproliferative effects of AR antagonists. It is therefore tempting to speculate that the loss of this induction is likely involved in the phenotypic changes allowing tumor cells to proliferate in the presence of low androgen levels, as observed in CRPCs (8) . This idea is supported by the inverse relationship existing between UGT2B15 and UGT2B17 expression and androgendependent PCa cell proliferation (14) , and by the strong influence that UGT2B15 and UGT2B17 polymorphisms exert on tissue androgen levels (35) . The loss of UGT genes sensitivity may allow PCa cells to maintain sufficient DHT levels to activate AR and its regulated genes in CRPCs (36, 37) . Based on these observations one can conclude that the UGTs induction in short-term treated samples is an important biochemical component of the initial ADTh benefits (38) . Following on that point, it can be envisioned that UGT2B15 and UGT2B17 are actually underexploited therapeutic targets for androgen deprivation therapies. Until now anti-androgenic approaches have been focusing on androgen biosynthesis and activity (38) . The present study validates the potential of targeting glucuronidation to reduce active androgen concentrations in PCa cells, thus providing a strong rational for searching pharmacological agents that stimulate androgen glucuronidation in PCa cells. However, such an alternative strategy requires the identification of AR-independent UGT2B15 and UGT2B17 genes inducers.
The present work may also have a significant impact in terms of PCa prognosis and diagnosis. Indeed, the respective changes in UGT2B15 and UGT2B17 protein levels in response to ADTh identify these 2 proteins as potential biomarkers for both evaluating the responsiveness to anti-androgen drug therapies and preventing resistance occurrence. ADTh remains the cornerstone of systemic treatments for locally advanced prostate cancer (37) , and biochemical predictors are currently needed to assess whether additional treatments should be initiated (39) . Furthermore, CRPC patients have a poor prognosis and account for the majority of PCa deaths (38), thus being able to anticipate ADTh resistance can be helpful in adapting (38) . A continuous follow-up of UGT2B15 and/or UGT2B17 intra-prostatic protein levels from the time of diagnosis constitutes a potential approach to evaluate therapy responsiveness, and measuring UGT2B17 levels may also be helpful to anticipate the loss of optimal ADTh effects in UGT2B17-positive patients, and then initiate alternative therapeutics, even before the resistance occurrence.
The above discussed diagnostic and therapeutic opportunities are mainly based on results from the tissue microarray study, while largely supported by results from functional investigations. However, sample heterogeneity is a major problem in tissue array studies, especially in PCa, where patients receive varied drugs or combination of drugs, and the tumor areas are small and often surrounded by normal cells (39) . Therefore, the role of UGT2B15 and 
